17.03
Novocure Ltd stock is traded at $17.03, with a volume of 1.81M.
It is down -3.51% in the last 24 hours and up +10.37% over the past month.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
See More
Previous Close:
$17.65
Open:
$17.97
24h Volume:
1.81M
Relative Volume:
1.01
Market Cap:
$1.97B
Revenue:
$674.41M
Net Income/Loss:
$-173.05M
P/E Ratio:
-11.10
EPS:
-1.5343
Net Cash Flow:
$-48.07M
1W Performance:
+6.84%
1M Performance:
+10.37%
6M Performance:
+30.50%
1Y Performance:
+41.45%
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
NVCR
Novocure Ltd
|
17.03 | 2.04B | 674.41M | -173.05M | -48.07M | -1.5343 |
|
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
Novocure Ltd (NVCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Novocure Posts Record Q2 Revenue of US$183.6M - Streetwise Reports
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
NovoCure Market Sentiment - Benzinga España
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade - Yahoo Finance Singapore
Novocure Ltd (NVCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NovoCure Ltd. (NVCRN) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
NovoCure (NVCR) Is Up 10.9% After Raising 2026 Revenue Outlook and Securing New CE Mark Approval – Has The Bull Case Changed? - simplywall.st
NovoCure Ltd. Revenue Breakdown – FWB:038 - TradingView
NovoCure Ltd. Revenue Breakdown – LSX:A140ML - TradingView
NovoCure Ltd. (NVCRN) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
NovoCure (NVCR) Lifts 2026 Guidance After Record Quarter While Fair Value Debate Builds - Yahoo Finance UK
TradingKey - TradingKey
Novocure Ltd (NVCR) Cash Flow - TradingKey
NovoCure (NVCR) Stock Faces Ongoing Losses As Q2 2026 EPS Narrows To $0.13 Loss - simplywall.st
Novocure Ltd (NVCR) Institutional Confidence - TradingKey
NVCR Maintained by Wedbush -- Price Target Raised to $20.00 - GuruFocus
H.C. Wainwright cuts NovoCure stock price target to $32 on valuation - Investing.com UK
Novocure Is Maintained at Neutral by Wedbush - Moomoo
NovoCure Posts Record Revenue and Raises Guidance, But NVCR Stock Tumbles Over 6% - finance.biggo.com
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding - Benzinga
Form 144 NovoCure Limited For: 24 July By Investing.com - Investing.com Nigeria
NovoCure Q2 2026 slides: profitability in sight, guidance raised By Investing.com - Investing.com Nigeria
Novocure Ltd (NVCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Novocure Ltd earnings beat by $0.20, revenue topped estimates - Investing.com Nigeria
Novocure Cash, Cash Equivalents and Short-Term Investments Were $440.6M as of June 30 >NVCR - Moomoo
NovoCure (NVCR) Breaks Out on Q2 2026 EarningsOptune Pax Driving Recovery - TradingKey
Novocure (NVCR) Hits New High on Optimistic Outlook, FDA Approval Hopes - Yahoo Finance
NVCR Maintained by HC Wainwright & Co. -- Price Target Raised to $52 - GuruFocus
Earnings call transcript: NovoCure beats Q2 2026 forecasts, shares jump 16% - Investing.com Nigeria
NovoCure Ltd SEC Filing (Jul 23, 2026) - Stock Titan
NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally? - Yahoo Finance
NovoCure Ltd (NVCR) Q2 2026 Earnings Call Highlights: Record Rev - GuruFocus
NovoCure Ltd (NVCR) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... - Yahoo Finance
NovoCure's Q2 Net Loss Narrows, Revenue Rises; 2026 Revenue Guidance Raised - Moomoo
NovoCure Shares Surge 29% on Q2 Results, 2026 Forecast Raised - TechStock²
Crude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 Results - Benzinga
Is Novocure Ltd (NVCR) Positioned for Growth After Q2 Earnings? - GuruFocus
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Top U.S. trending stocks: NovoCure leads with 23.4% surge - Investing.com
NovoCure surges on Q2 resultsGlobes - Globes - Israel Business News
Novocure stock hits 52-week high at 19.49 USD By Investing.com - Investing.com Nigeria
NovoCure Ltd Q2 2026 Financial Results: Revenue, R&D, and Key Risks Highlighted in Latest 10-Q Filing - Minichart
Novocure Reports Record Second-Quarter Revenue as Optune Expansion Drives Higher 2026 Outlook - Yahoo Finance
Earnings call transcript: NovoCure beats Q2 2026 forecasts, shares jump 16% By Investing.com - Investing.com South Africa
Novocure stock hits 52-week high at 19.49 USD - Investing.com
Novocure Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
NovoCure Q2 2026 slides: profitability in sight, guidance raised - Investing.com
Transcript: NovoCure Q2 2026 Earnings Conference Call - Benzinga
NovoCure Q2 Earnings Call Highlights - Yahoo Finance
NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):